Colony-stimulating factor-1 antisense treatment suppresses growth of human tumor xenografts in mice

Seyedhossein Aharinejad1, Dietmar Abraham, Patrick Paulus

  • 1Laboratory for Cardiovascular Research, Department of Anatomy, University of Vienna, Waehringerstrasse 13, A-1090 Vienna, Austria. ahas@univie.ac.at

Cancer Research
|September 18, 2002
PubMed

Insights

Blocking colony-stimulating factor-1 (CSF-1) with antisense oligonucleotides suppressed tumor growth and improved survival in preclinical models. This strategy targets macrophage-mediated matrix breakdown, offering a novel approach for solid tumor treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • Matrix metalloproteinases (MMPs) facilitate tumor invasion by degrading the extracellular matrix.
  • MMPs are produced by cancer cells and stromal cells, notably macrophages.
  • Macrophage production is regulated by colony-stimulating factor-1 (CSF-1), which is upregulated in certain cancers.

Purpose of the Study:

  • To investigate if blocking CSF-1 can inhibit tumor growth by reducing macrophage-mediated extracellular matrix breakdown.
  • To evaluate the efficacy of CSF-1 blockade in preclinical models of human embryonic and colon cancer.

Main Methods:

  • Utilized CSF-1 antisense oligonucleotides to down-regulate CSF-1 expression in mice xenografted with cancer cells.
  • Assessed changes in CSF-1 mRNA and protein levels, tumor growth, vascularity, MMP-2 expression, and survival rates.

Main Results:

  • CSF-1 blockade significantly reduced CSF-1 expression in tumor tissues.
  • Tumor growth was suppressed, with embryonic tumors becoming dormant and colon carcinomas reduced by 50%.
  • Reduced tumor vascularity, MMP-2, and angiogenic factor expression were observed, leading to improved survival in colon cancer models.

Conclusions:

  • Cancer cells upregulate host CSF-1 and MMP-2 expression.
  • Targeting stromal CSF-1 production via antisense therapy is effective in suppressing tumor growth and enhancing survival.
  • CSF-1 blockade represents a potential novel therapeutic strategy for solid tumors.